Skip to main content
AmigoFish

Psychopharmacology and Psychiatry Updates

Psychopharmacology InstituteAudio

Format:
Podcast
New episodes:
Weekly
Typical length:
about 15 minutes
Latest episode:
Not rated yet
CosmosOpen at the sourceReport a problemIs this your show? Get a badge

About this show

Practical psychopharmacology updates for mental health clinicians. Useful for psychiatry / mental health professionals. Expert interviews and soundbites from CME presentations. Practical and free of commercial bias. Not sponsored by any pharmaceutical company.

Covers: psychiatry, psychopharmacology, antipsychotic medications, antidepressant treatment, ocd treatment, ptsd treatment, insomnia treatment, addiction medicine

Show details and episodes come from the publisher's public feed at psychopharmacology.libsyn.com. Last updated . Names, artwork and text belong to their publishers.

Recently on this show

Summary of recent episodes, drawn from the publisher's feed.

This podcast gives mental health clinicians practical updates on psychopharmacology, drawing on expert interviews and presentation excerpts. Recent episodes cover adjunctive antipsychotics for major depression, buprenorphine and methadone in liver disease, catatonia treatment, prazosin for PTSD nightmares, and Z-drugs in early pregnancy.

Report a problem with this summary

Cosmos

Similar in subject

See the full Cosmos

Similar shows

See all Health shows

Explore more

Episodes

  • GLP-1s and Lithium: What Clinicians Need to Know

    · 11 min

    In this episode, we explore a surprising drug interaction that every lithium-prescribing clinician should know about: can semaglutide, the widely used GLP-1 receptor agonist, push lithium levels into toxic territory — and if so, why? Faculty: Paul Zarkowski, M.D. Host: Richard Seeber, M.D. - Learn more about our membership here - Earn 0.75 CMEs: Quick Take Vol. 83 - Can GLP-1 Agonists Elevate Lithium Levels?

    Not rated yet
  • Naltrexone for Alcohol Use Disorder: What You Should Know

    · 13 min

    In this episode, we explore how naltrexone — the most widely used medication for alcohol use disorder in the US — works, how to dose it safely, and why liver disease may not be the barrier you think it is. Can a medication that doesn't target abstinence still be a game-changer for your patients? Faculty: Kevin A. Sevarino, M.D.C.M., Ph.D Host: Richard Seeber, M.D. - Learn more about our memberships here - Earn 1.25 CME: Pharmacotherapy of Alcohol Use Disorder - Naltrexone for Alcohol Use Disorder: Dosing, Monitoring, and Liver Safety

    Not rated yet
  • The OPTIMUM Trial: A Roadmap for Treatment-Resistant Depression in Late Life

    · 16 min

    In this episode, we explore the OPTIMUM trial, a landmark study examining how to treat older adults with treatment-resistant depression when antidepressants fall short. When adding a medication outperforms switching entirely — and what that means for the patient sitting across from you — the answer may reshape your clinical approach. Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D. - Learn more about our membership here - Earn 0.75 CMEs: Quick Take Vol. 83 - Antidepressant Augmentation vs. Switching in Geriatric Depression: Key Findings from the OPTIMUM Trial

    Not rated yet
  • Difficult-to-Treat Depression: First, Second, and Third-Line Strategies

    · 15 min

    In this episode, we explore what to do when antidepressants aren't working. How do you systematically approach a patient who isn't getting better — and when do you switch versus augment? Dr. Sagar Parikh walks through CANMAT's evidence-based framework for difficult-to-treat depression. Faculty: Sagar V. Parikh, M.D., F.R.C.P.C. Host: Richard Seeber, M.D. - Learn more about our memberships here - Earn 1.25 CME: Rethinking Depression Treatment: An Update of CANMAT's Guidelines - Pharmacologic Management of Difficult-to-Treat Depression: First, Second, and Third Line Options

    Not rated yet
  • Is High-Dose Olanzapine A Clozapine Alternative?

    · 10 min

    In this episode, we explore whether high-dose olanzapine — beyond the FDA-approved 20 mg ceiling — can be a viable strategy for patients with treatment-resistant schizophrenia when clozapine isn't yet an option. Can pushing the dose bridge the gap between partial response and full remission? Faculty: Oliver Freudenreich, M.D. Host: Richard Seeber, M.D. - Learn more about our membership here - Earn 0.75 CME: Quick Take Vol. 83 - Treatment-Resistant Schizophrenia: Should You Consider High-Dose Olanzapine Instead of Clozapine?

    Not rated yet
  • CANMAT Guidelines: Herbs, Supplements, and Depression

    · 7 min

    In this episode, we explore what the CANMAT guidelines say about complementary and alternative medicine (CAM) for depression — from St. John's wort to saffron — and how to have evidence-based, collaborative conversations with patients who prefer a more natural approach to treatment. Faculty: Sagar V. Parikh, M.D., F.R.C.P.C. Host: Richard Seeber, M.D. - Learn more about our memberships here - Earn 1.25 CME: Rethinking Depression Treatment: An Update of CANMAT's Guidelines - Complementary and Alternative Medicine for Depression: CANMAT Recommendations

    Not rated yet
  • Xylazine in the ED: Managing Toxicity

    · 9 min

    In this episode, we explore the growing threat of xylazine — a veterinary sedative increasingly found in illicit drug supplies — and what clinicians need to know when naloxone simply isn't enough. Dr. David Gorelick breaks down the current evidence on diagnosis, treatment, and the critical gaps that remain. Faculty: David A. Gorelick, M.D., Ph.D., D.L.F.A.P.A., F.A.S.A.M. Host: Richard Seeber, M.D. - Learn more about our membership here - Earn 0.5 CME: Quick Take Vol. 82 - Xylazine ("Tranq Dope") Overdose: What Clinicians Should Know

    Not rated yet
  • Choosing the First Step in Depression Treatment: A CANMAT Guide

    · 18 min

    In this episode, we explore how to select the right initial treatment for depression using the updated CANMAT guidelines. How do severity, patient preference, and treatment availability shape your first clinical move? Dr. Sagar Parikh breaks down the evidence on psychotherapy, antidepressants, and when to combine both. Faculty: Sagar V. Parikh, M.D. Host: Richard Seeber, M.D. - Learn more about our memberships here - Earn 1.25 CME: Rethinking Depression Treatment: An Update of CANMAT's Guidelines - Selecting the Initial Depression Treatment

    Not rated yet
  • After Delirium Clears: When to Deprescribe?

    · 14 min

    In this episode, we explore the hidden dangers of leaving antipsychotics running long after a hospital delirium episode has resolved. Could a medication prescribed to keep your patient safe in the short term actually be harming them months later — and what does the latest evidence say about stopping it? Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D. - Learn more about our membership here - Earn 0.5 CME: Quick Take Vol. 82 - Deprescribing Antipsychotics Post-Delirium: Why It Matters

    Not rated yet
  • The Clinician's Guide to Paliperidone & Risperidone LAIs

    · 15 min

    In this episode, we explore the practical dosing, initiation, and conversion strategies for paliperidone palmitate and risperidone long-acting injectables in schizophrenia. How do you manage a missed six-month injection — reload or continue? Dr. Brian Miller breaks down everything you need to know to prescribe these formulations with confidence. Faculty: Brian Miller, M.D., Ph.D., M.P.H. Host: Richard Seeber, M.D. - Learn more about our memberships here - Earn 0.75 CME: Use of Long-Acting Injectable Antipsychotics in Schizophrenia - LAIs in Practice: Paliperidone & Risperidone

    Not rated yet
  • Antipsychotic Switching: Six Clinical Tips

    · 12 min

    In this episode, we explore the surprisingly thin evidence base behind antipsychotic switching — one of psychiatry's most common clinical maneuvers. Dr. Oliver Freudenreich breaks down a landmark systematic review and shares six practical tips to help clinicians switch antipsychotics safely and confidently. Faculty: Oliver Freudenreich, M.D. Host: Richard Seeber, M.D. - Learn more about our membership here - Earn 0.5 CMEs: Quick Take Vol. 82 - Switching Oral Antipsychotics: Six Strategies and Tips

    Not rated yet
  • Mastering Long-Acting Injectables: Aripiprazole & Olanzapine

    · 11 min

    In this episode, we explore the practical use of long-acting injectable antipsychotics in schizophrenia — specifically aripiprazole and olanzapine formulations. What's the right dose when a patient misses an injection? Dr. Brian Miller breaks down dosing, oral supplementation windows, and dose equivalence for Abilify Maintena, Aristada, and Zyprexa Relprevv. Faculty: Brian Miller, M.D., Ph.D., M.P.H. Host: Richard Seeber, M.D. - Learn more about our memberships here - Earn 0.75 CME: Use of Long-Acting Injectable Antipsychotics in Schizophrenia - LAIs in Practice: Aripiprazole & Olanzapine

    Not rated yet
  • Preventing Relapse: The Role of LAIs in Schizophrenia

    · 7 min

    In this episode, we explore when and why long-acting injectable antipsychotics (LAIs) should be considered for patients with schizophrenia, covering approved indications, ideal candidate profiles, and the critical role of shared decision-making in treatment planning. Faculty: Brian Miller, M.D., Ph.D., M.P.H. Host: Richard Seeber, M.D. - Learn more about our memberships here - Earn 0.75 CME: Use of Long-Acting Injectable Antipsychotics in Schizophrenia - Understanding When to Prescribe LAIs

    Not rated yet
  • Could Lithium Play a Role in Preventing Alzheimer's Disease?

    · 11 min

    In this episode, we explore a striking new Nature study suggesting that lithium deficiency may play a central role in the onset of Alzheimer's disease. Could a simple, overlooked supplement be the key to prevention? Dr. Scott Beach unpacks the science, the promise, and the important caveats. Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D. - Learn more about our membership here - Earn 0.5 CME: Quick Take Vol. 81 - Lithium Orotate: Breakthrough Treatment for Alzheimer's Disease?

    Not rated yet
  • Managing ADHD in Pregnancy: Weighing Risk versus Risk

    · 8 min

    In this episode, we explore the nuanced challenge of managing ADHD with stimulant medications during pregnancy. Is stopping the medication always the safer choice — or does untreated ADHD carry risks of its own? Dr. Amanda Koire breaks down the latest evidence to help clinicians make truly informed decisions. Faculty: Amanda Koire, M.D., Ph.D. Host: Richard Seeber, M.D. - Learn more about our memberships here - Earn 0.5 CME: Prescribing in Pregnancy: What Every Clinician Should Know - Pregnancy, ADHD, and Stimulants: Making an Informed Choice

    Not rated yet
  • Ondansetron for Negative Symptoms of Schizophrenia

    · 13 min

    In this episode, we examine a surprising repurposing of ondansetron — a common antiemetic — as a potential adjunctive treatment for the notoriously hard-to-treat negative symptoms of schizophrenia. Could a nausea medication help restore motivation and emotional engagement in your patients with residual symptoms despite stable antipsychotic therapy? Faculty: Oliver Freudenreich, M.D. Host: Richard Seeber, M.D. - Learn more about our membership here - Earn 0.5 CMEs: Quick Take Vol. 81 - Is Ondansetron Effective for Negative Symptoms in Schizophrenia?

    Not rated yet
  • Managing SSRIs During Pregnancy: Myths vs. Evidence

    · 7 min

    In this episode, we explore how to manage SSRI treatment in pregnant patients — addressing common fears around fetal malformations, medication switching, and neonatal withdrawal. Can stopping an antidepressant actually do more harm than continuing it? Faculty: Amanda Koire, M.D. Host: Richard Seeber, M.D. - Learn more about our memberships here - Earn 0.5 CME: Prescribing in Pregnancy: What Every Clinician Should Know - SSRI Treatment During Pregnancy: A Clinical Case

    Not rated yet
  • Rethinking Haloperidol's Cardiac Risk

    · 14 min

    In this episode, we explore a landmark meta-analysis that challenges decades of fear surrounding IV haloperidol and cardiac risk. Could one of medicine's most persistent myths be costing patients their best treatment option for delirium? Dr. Scott Beach breaks down the evidence. Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D. - Learn more about our membership here - Earn 0.75 CMEs: Quick Take Vol. 80 - IV Haloperidol: Are Cardiac Safety Concerns Overblown?

    Not rated yet
  • Bipolar Disorder, Lithium, and Pregnancy: What the Evidence Says

    · 11 min

    In this episode, we explore the complex risk-versus-risk decision of using lithium during pregnancy and breastfeeding. How do you weigh the near-certainty of mood relapse against fetal cardiac risks? Dr. Amanda Koire provides a practical framework every clinician needs when managing bipolar disorder in reproductive-age women. Faculty: Amanda Koire, M.D. Host: Richard Seeber, M.D. - Learn more about our memberships here - Earn 0.5 CME: Prescribing in Pregnancy: What Every Clinician Should Know - Lithium in Pregnancy and Breastfeeding

    Not rated yet
  • Clozapine Monitoring: New Guidelines for the Post-REMS Era

    · 12 min

    In this episode, we explore new international guidelines for clozapine monitoring following the FDA's REMS rescission. Should patients on stable clozapine continue lifelong monthly blood draws, or can we safely reduce monitoring after two years? Dr. Seeber discusses how these evidence-based recommendations balance patient burden with safety. Faculty: Oliver Freudenreich, M.D. Host: Richard Seeber, M.D. - Learn more about our membership here - Earn 0.75 CMEs: Quick Take Vol. 79 - New Guidelines for Clozapine ANC Monitoring

    Not rated yet